“…10,11 Retrograde loss of nerve fibres in the retina and optic nerve may be an early biomarker of neurodegeneration in AD, even before hippocampal damage, which leads to memory impairment. 12 Recent studies have revealed the value of RNFL and macular measurements provided by OCT for detecting neurodegenerative disease progression and facilitating the diagnosis of diseases such as multiple sclerosis 10,13,14 and Parkinson's disease. 15,16 Therefore, in the present study we evaluated the reliability of retinal and RNFL applications of the two most commonly available FD-OCT devices, the Cirrus (Carl Zeiss Meditec Inc., Dublin, CA, USA) and Spectralis (Heidelberg Engineering, Inc., Heidelberg, Germany), for detecting retinal thinning and RNFL atrophy in patients with AD.…”